*Revenue expected flat-ish at € 22.6m (eNuW), EBITDA +24.5% yoy to € 0.7m (eNuW: 3.2%
margin) supported by internal optimization.
*Disinfection (eNuW: +7.9%) and Adhesives (eNuW: +6.8%) growth offsets Curing
weakness (eNuW: -12.1%, still EBITDA-negative).
*Further cost right-sizing at Curing expected.
LÄS MER